US · KPTI
Karyopharm Therapeutics Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Newton, MA 02459
- Website
- karyopharm.com
Price · as of 2025-12-31
$8.77
Market cap 80.34M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $16.45 | +87.57% |
| Intrinsic Value(DCF) | $3.84 | -56.21% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $633.45 | $265.19 | $278.26 | $0.00 | $2,448.31 |
| 2014 | $421.20 | $177.18 | $57.24 | $0.00 | $1,127.89 |
| 2015 | $118.50 | $49.99 | $27.21 | $0.00 | $0.00 |
| 2016 | $158.25 | $63.30 | $14.78 | $0.00 | $1,252.79 |
| 2017 | $252.90 | $101.16 | $522.82 | $0.00 | $0.00 |
| 2018 | $63.30 | $132.30 | $17,900,549.13 | $0.00 | $0.00 |
| 2019 | $375.30 | $150.12 | $440,988.50 | $0.00 | $0.00 |
| 2020 | $184.65 | $73.86 | $5,350,523.20 | $0.00 | $0.00 |
| 2021 | $94.95 | $72.47 | $2,334,022.05 | $0.00 | $0.00 |
| 2022 | $45.00 | $18.00 | $14,053.39 | $0.00 | $483.75 |
| 2023 | $23.55 | $17.63 | $0.00 | $0.00 | $0.00 |
| 2024 | $6.89 | $2.76 | $0.00 | $0.00 | $0.00 |
| 2025 | $9.59 | $16.45 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Karyopharm Therapeutics Inc.'s (KPTI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $16.45
- Current price
- $8.77
- AI upside
- +87.57%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.84
-56.21% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KPTI | Karyopharm Therapeutics I… | $8.77 | 80.34M | +88% | -56% | — | — | -0.53 | -0.36 | 0.72 | -3.04 | -0.59 | -0.36 | 95.93% | -62.10% | -134.21% | 81.86% | 81.25% | -143.71% | -0.80 | -1.98 | 1.12 | 0.98 | -1.91 | 9054.00% | 57.00% | -4095.00% | -71.87% | -0.82 | 67.51% | 0.00% | 0.00% | 0.00% | -3.03 | -3.65 | 1.88 | -23.86 |
| ALGS | Aligos Therapeutics, Inc. | $7.03 | 43.26M | -26% | -26% | — | +18,737% | -0.62 | -2.80 | 20.55 | -0.38 | -0.12 | -2.80 | 100.00% | -2259.92% | -3326.01% | -415.84% | 162.06% | -118.41% | -0.29 | — | 2.86 | 2.62 | 0.33 | 49489.00% | -7460.00% | 235.00% | -99.76% | -3.71 | 147.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 8.24 | -15.30 |
| BRNS | Barinthus Biotherapeutics… | $0.58 | 23.85M | +43,665% | +73% | — | — | -0.63 | 0.30 | 2.59 | 1.08 | — | 0.36 | 100.00% | -454.07% | -408.00% | -38.62% | -152.56% | -32.65% | 0.09 | -1282.45 | 8.03 | 7.90 | 1.78 | -1885.00% | 176646.00% | -4705.00% | -76.97% | -1.85 | -67.01% | 0.00% | 0.00% | 0.00% | 0.88 | 2.01 | -4.00 | -1.79 |
| FGEN | FibroGen, Inc. | $9.07 | 36.69M | +230% | -59% | — | +42% | -19.49 | -4.11 | 31.31 | -6.67 | — | -4.11 | 47.47% | -507.80% | -160.63% | 22.14% | 63.58% | -14.91% | -0.32 | -18.24 | 1.47 | 0.60 | -0.16 | -8356.00% | -3671.00% | -5646.00% | -14.91% | -1.04 | 58.55% | 0.24% | -4.70% | 3.92% | -6.32 | -6.87 | 32.07 | -12.76 |
| INMB | INmune Bio, Inc. | $1.29 | 34.29M | +2,143% | +149% | — | +12,808% | -3.80 | 4.98 | 11425.06 | -3.31 | -14.43 | 10.26 | 100.00% | -304535.71% | -300585.71% | -119.83% | -351.09% | -87.16% | 0.01 | — | 3.14 | 3.09 | 0.49 | 2635.00% | -9097.00% | 17847.00% | -20.86% | -4.62 | -274.72% | 0.00% | 0.00% | 0.00% | -3.27 | -4.18 | 9958.06 | 4.00 |
| MDCX | Medicus Pharma Ltd. Commo… | $1.53 | 37.8M | — | — | — | — | -2.63 | 9.36 | — | -2.29 | — | 9.36 | 0.00% | — | — | -525.44% | 1700.21% | -295.90% | 0.10 | -35.21 | 2.33 | 1.81 | 0.34 | -2810.00% | — | 14643.00% | -34.93% | -4.44 | 1558.23% | 0.00% | 0.00% | 7.24% | -2.28 | -2.49 | — | -6.04 |
| MRSN | Mersana Therapeutics, Inc… | $29.08 | 145.36M | +85% | +9,159% | — | — | -0.96 | -7.01 | 1.65 | 0.62 | — | -7.01 | 95.98% | -181.09% | -170.86% | -505.14% | 57.77% | -37.33% | -3.01 | -18.93 | 2.19 | 2.16 | 1.25 | -6180.00% | 988.00% | -5178.00% | -123.65% | -1.32 | 64.97% | 0.00% | 0.00% | 0.00% | 0.54 | 0.48 | -0.97 | -9.18 |
| SNTI | Senti Biosciences, Inc. | $0.94 | 24.82M | +2,578% | — | — | — | -0.31 | 0.63 | — | -0.03 | — | 0.63 | 0.00% | — | — | -114.06% | -153.24% | -48.58% | 1.31 | — | 4.49 | 3.81 | 0.27 | -4513.00% | -10000.00% | -3571.00% | -256.05% | -3.15 | -103.99% | 0.00% | 0.00% | 101.22% | -0.03 | -0.04 | — | -5.61 |
| TELO | Telomir Pharmaceuticals, … | $1.27 | 43.66M | — | — | — | — | -7.77 | 199.83 | — | 2652.56 | -28.50 | 199.83 | 0.00% | — | — | -810.18% | -813.89% | -542.25% | 0.15 | 2.82 | 1.94 | 1.86 | -24.43 | 2727.00% | — | 3137.00% | -3.95% | -7.45 | -337.09% | 0.00% | 0.00% | 0.99% | -10.40 | -25.11 | — | 50.93 |
| XFOR | X4 Pharmaceuticals, Inc. | $3.44 | 39.24M | — | +23% | — | — | -1.89 | 3.20 | 27.68 | -1.70 | — | -13.60 | 68.83% | -1423.58% | -1464.61% | -102.26% | 1092.96% | -25.50% | 3.53 | -4.15 | 3.41 | 3.16 | -0.81 | -6731.00% | — | 3589.00% | -185.42% | -3.98 | 3940.16% | 0.00% | 0.00% | 0.00% | -1.29 | -0.36 | 18.30 | -4.74 |
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
- CEO
- Richard A. Paulson
- Employees
- 279
- Beta
- 0.22
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.84 ÷ $8.77) − 1 = -56.21% (DCF, example).